# Dikhnah Alshehri, et al.: Gut microbiota in IBD therapy

# References

1. Duncan SH, et al. Faecalibacterium prausnitzii strain HTF-F and its extracellular polymeric matrix attenuate clinical parameters in DSS-induced colitis. PLoS One 2015;10(4):e0123013. https://doi.org/10.1371/journal.pone.0123013.
2. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 2011;5(2):220-30. https://doi.org/10.1038/ismej.2010.118.
3. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Investig 2007;117(3):514-21. https://doi.org/10.1172/jci30587.
4. Eichele DD, Kharbanda KK. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J Gastroenterol 2017;23(33):6016-29. https://doi.org/10.3748/wjg.v23.i33.6016.
5. De Fazio L, Cavazza E, Spisni E, Strillacci A, Centanni M, Candela M, et al. Longitudinal analysis of inflammation and microbiota dynamics in a model of mild chronic dextran sulfate sodium-induced colitis in mice. World J Gastroenterol 2014;20(8):2051. https://doi.org/10.3748/wjg.v20.i8.2051.
6. Gkouskou K, Deligianni C, Tsatsanis C, Eliopoulos AG. The gut microbiota in mouse models of inflammatory bowel disease. Front Cell Infect Microbiol 2014;4:28. https://doi.org/10.3389/fcimb.2014.00028.
7. D’haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114(2):262-7. https://doi.org/10.1016/s0016-5085(98)70476-7.
8. Dicksved J, Schreiber O, Willing B, Petersson J, Rang S, Phillipson M, et al. Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment despite mucus layer dysfunction. PLoS One 2012;7(9):e46399. https://doi.org/10.1371/journal.pone.0046399.
9. McIlroy J, Ianiro G, Mukhopadhya I, Hansen R, Hold G. The gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther 2018;47(1):26-42. https://doi.org/10.1111/apt.14384.
10. Hansen R, Berry SH, Mukhopadhya I, Thomson JM, Saunders KA, Nicholl CE, et al. The microaerophilic microbiota of de-novo paediatric inflammatory bowel disease: The BISCUIT study. PLoS One 2013;8(3):e58825. https://doi.org/10.1371/journal.pone.0058825.
11. Hansen R, Russell RK, Reiff C, Louis P, McIntosh F, Berry SH, et al. Microbiota of de-novo pediatric IBD: Increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn’s but not in ulcerative colitis. Am J Gastroenterol 2012;107(12):1913. https://doi.org/10.1038/ajg.2012.335.
12. Lopez-Siles M, Khan TM, Duncan SH, Harmsen HJ, Garcia-Gil LJ, Flint HJ. Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth. Appl Environ Microbiol 2012;78(2):420-8. https://doi.org/10.1128/aem.06858-11.
13. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014;15(3):382-92. https://doi.org/10.1016/j.chom.2014.02.005.
14. Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Köhler H. Microbiota in pediatric inflammatory bowel disease. J Pediatr 2010;157(2):240-4. https://doi.org/10.1016/j.jpeds.2010.02.046.
15. Fujimoto T, Imaeda H, Takahashi K, Kasumi E, Bamba S, Fujiyama Y, et al. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn’s disease. J Gastroenterol Hepatol 2013;28(4):613-9. https://doi.org/10.1111/jgh.12073.
16. Pirzer U, Schönhaar A, Fleischer B, Hermann E, Büschenfelde KH. Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn’s disease. Lancet (London, England) 1991;338(8777):1238-9. https://doi.org/10.1016/0140-6736(91)92104-a.
17. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38(3):365-75. https://doi.org/10.1136/gut.38.3.365.
18. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007;102(9):2058-69.
19. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper Type 1 and 2 lineages. Nat Immunol 2005;6(11):1123-32. https://doi.org/10.1038/ni1254.
20. Günther C, Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H, et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature 2011;477(7364):335-9. https://doi.org/10.1038/nature10400.
21. Perrier C, De Hertogh G, Cremer J, Vermeire S, Rutgeerts P, Van Assche G, et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis 2013;19(2):246-53. https://doi.org/10.1002/ibd.23023.
22. Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol 2019;20(8):970-9. https://doi.org/10.1038/s41590-019-0415-0.
23. Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: Time for a change. Gut 2011;60(12):1754-63. https://doi.org/10.1136/gutjnl-2011-300934.
24. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet 2002;359(9317):1541-9. https://doi.org/10.1016/s0140-6736(02)08512-4.
25. Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 2017;152(2):327-39. https://doi.org/10.1053/j.gastro.2016.10.012.
26. Buttó LF, Haller D. Dysbiosis in intestinal inflammation: Cause or consequence. Int J Med Microbiol 2016;306(5):302-9.
27. Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010;139(6):1816-9. https://doi.org/10.1053/j.gastro.2010.10.036.
28. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011;145(5):745-57. https://doi.org/10.1016/j.cell.2011.04.022.
29. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119(2):305-9. https://doi.org/10.1053/gast.2000.9370.
30. Huttenhower C, Knight R, Brown CT, Caporaso JG, Clemente JC, Gevers D, et al. Advancing the microbiome research community. Cell 2014;159(2):227-30.
31. Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host Microbe 2015;18(4):489-500. https://doi.org/10.1016/j.chom.2015.09.008.
32. Patwa LG, Fan TJ, Tchaptchet S, Liu Y, Lussier YA, Sartor RB, et al. Chronic intestinal inflammation induces stress-response genes in commensal Escherichia coli. Gastroenterology 2011;141(5):1842-51. https://doi.org/10.1053/j.gastro.2011.06.064.
33. Eun CS, Mishima Y, Wohlgemuth S, Liu B, Bower M, Carroll IM, et al. Induction of bacterial antigen-specific colitis by a simplified human microbiota consortium in gnotobiotic interleukin-10-/- mice. Infect Immun 2014;82(6):2239-46. https://doi.org/10.1128/iai.01513-13.

Bosn J Basic Med Sci. 2021;21(3):270-283

www.bjbms.org